| Literature DB >> 33932977 |
Stéphane Fabre1, Carole Moreno-Romieux2, Maxime Ben Braiek2, Chris Hozé3, Jean-Michel Astruc4.
Abstract
BACKGROUND: Homozygous recessive deleterious mutations can cause embryo/fetal or neonatal lethality, or genetic defects that affect female fertility and animal welfare. In livestock populations under selection, the frequency of such lethal mutations may increase due to inbreeding, genetic drift, and/or the positive pleiotropic effects of heterozygous carriers on selected traits.Entities:
Mesh:
Year: 2021 PMID: 33932977 PMCID: PMC8088666 DOI: 10.1186/s12711-021-00634-1
Source DB: PubMed Journal: Genet Sel Evol ISSN: 0999-193X Impact factor: 5.100
Description of genotyped animals
| Year of birth | ≤ 2014 | 2015–2016 | ≥ 2017 | Total | |
|---|---|---|---|---|---|
| Background | Research programs | Genomic selection | Genomic selection | ||
| Number of animals | 6587 rams | 3986 rams | 7012 rams | 19,102 | |
| 1517 ewes | |||||
| SNP chip | MD | MD | LD (n = 6502) | MD (n = 510) | LD (n = 6502) |
| MD (n = 12,600) | |||||
| Genotyping age (months) | > 12 | 1–5 | 1–5 | 8–12 | |
MD medium density (50 k), LD low density (15 k)
List of Lacaune deficient homozygous haplotypes
| Haplotype | OAR | Number of markersa | Positionb (Mb) | Carrier frequencyc (%) | Number of homozygotes | |||
|---|---|---|---|---|---|---|---|---|
| Expd | Obse | Deficit (%) | Poisson P-value | |||||
| LDHH1 | 4 | 46/42 | 43.4–46.3 | 6.7 | 21 | 0 | 100 | 7.6 × 10−10 |
| LDHH2 | 13 | 28/26 | 44.8–46.8 | 6.2 | 17 | 0 | 100 | 4.1 × 10−8 |
| LDHH3 | 3 | 48/39 | 32.0–34.9 | 4.3 | 10 | 0 | 100 | 7.0 × 10−5 |
| LDHH4 | 3 | 24/19 | 132.4–133.9 | 3.8 | 10 | 0 | 100 | 5.5 × 10−5 |
| LDHH5 | 3 | 29/23 | 131.1–132.7 | 3.7 | 9 | 0 | 100 | 1.9 × 10−4 |
| LDHH6 | 3 | 27/21 | 136.2–137.4 | 12.1 | 72 | 3 | 96 | 3.5 × 10−27 |
| LDHH7 | 17 | 29/27 | 0.0–1.6 | 4.7 | 12 | 1 | 92 | 9.9 × 10−5 |
| LDHH8 | 18 | 23/20 | 25.7–27.5 | 5.5 | 14 | 2 | 86 | 9.4 × 10−5 |
| LDHH9 | 18 | 37/33 | 31.3–33.5 | 4.4 | 13 | 2 | 85 | 2.2 × 10−4 |
| LDHH10 | 18 | 26/23 | 33.0–34.6 | 5.7 | 17 | 3 | 82 | 4.1 × 10−5 |
| LDHH11 | 3 | 28/28 | 128.9–131.1 | 7.2 | 19 | 4 | 79 | 3.8 × 10−5 |
aNumber of LDHH markers refers to ovine genome reference assembly Oar_v2.0/Oar_v3.1 and listed in Additional file 2: Table S3
bPosition on ovine genome assembly Oar_v3.1
cFrequency of carriers in the entire genotyping population (n = 19,102)
dExpected
eObserved
Fig. 1Effects of LDHH on the success rate of artificial insemination and on the stillbirth rate in at-risk matings compared to safe matings. AIS artificial insemination success, SBR stillbirth rate. For each LDHH, the frequency of at-risk mating is shown in parentheses. Significant effects are indicated by the corrected P-value for multiple tests with a threshold set at α = 1%: *P < 6.3 × 10−4; **P < 6.3 × 10−5 and ***P < 6.3 × 10−6
Fig. 2sDYD relative difference between heterozygous and non-carrier rams for 6 selected traits. MY milk yield, FY fat yield, PY protein yield, FC fat content, PC protein content, LSCS Lactation somatic cell score, sDYD standardized daughter yield deviation (DYD divided by genetic standard deviation). Significant effects are indicated by the corrected P-value for multiple tests with a threshold set at α = 1%: *P < 3.1 × 10−4; **P < 3.1 × 10−5 and ***P < 3.1 × 10−6. Error bars indicate standard errors. Significant favorable effects of heterozygous are in green and significant unfavorable effects are in red
Most probable candidate genes affecting viability in mouse knockout models and associated with mammalian autosomal recessive disorders
| Haplotype | Gene namea | Gene description | Mammalian recessive disorderb |
|---|---|---|---|
| LDHH1 | Membrane associated guanylate kinase, WW and PDZ domain containing 2 | Nephrotic syndrome | |
| Peptidase, mitochondrial processing beta subunit | Multiple mitochondrial dysfunctions syndrome | ||
| Reelin | Lissencephaly and cerebellar hypoplasia | ||
| LDHH2 | Isopentenyl-diphosphate delta isomerase 1 | Zellweger syndrome and neonatal adrenoleukodystrophy | |
| Major prion protein | Spongiform encephalopathy | ||
| Proliferating cell nuclear antigen | Ataxia-telangiectasia-like disorder | ||
| Fermitin family member 1 | Kindler syndrome | ||
| LDHH3 | Proopiomelanocortin | Obesity, adrenal insufficiency | |
| Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha/beta | Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency with myopathy and neuropathy | ||
| Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase | Abortion; epileptic encephalopathy, early infantile | ||
| Eukaryotic translation initiation factor 2B subunit delta | Leukoencephalopathy, ovarioleukodystrophy | ||
| Intraflagellar transport 172 | Retinitis pigmentosa, short-rib thoracic dysplasia ± polydactyly | ||
| LDHH4–5 | Homeobox C13 | Ectodermal dysplasia | |
| Keratin 8 | Cryptogenic cirrhosis | ||
| Sodium voltage-gated channel alpha subunit 8 | Spinocerebellar ataxia | ||
| LDHH6 | Wnt family member 1 | Osteogenesis imperfecta, type XV | |
| Coiled-coil domain containing 65 | Primary ciliary dyskinesia | ||
| Phosphofructokinase, muscle | Glycogen storage disease VII | ||
| LDHH7 | Tolloid like 1 | Heart malformation | |
| LDHH8-9–10 | Fumarylacetoacetate hydrolase | Tyrosinemia | |
| Aryl hydrocarbon receptor nuclear translocator 2 | Webb-Dattani syndrome | ||
| Mannose phosphate isomerase | Congenital disorder of glycosylation, type Ib | ||
| Cytochrome P450 family 1 subfamily A member 2 | Metabolizer of a cognitive enhancer | ||
| Stimulated by retinoic acid 6 | Microphthalmia | ||
| LDHH11 | CASP2 and RIPK1 domain containing adaptor with death domain | Mental retardation, with variant lissencephaly | |
| Centrosomal protein 83 | Nephronophthisis |
aHomozygous lethal† (complete penetrance) and homozygous sub-viable* (incomplete penetrance) genes affecting developmental stages reported in knockout databases (IMPC and/or MGI)
bMammalian autosomal recessive disorders reported in OMIM and/or OMIA databases